Surgery Partners, Inc. Reaffirms 2023 Full Year Guidance and Provides 2024 Initial Adjusted EBITDA Outlook
BRENTWOOD, Tenn., Jan. 08, 2024 (GLOBE NEWSWIRE) — Members of management of Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, will be meeting with investors today, January 8, 2024, as part of the 42nd Annual J.P. Morgan Healthcare Conference, including a presentation at 5:15 p.m. ET. Based on results through November 2023, the Company is re-affirming its 2023 Adjusted EBITDA guidance of $436 million to $440 million and its 2023 Revenue guidance of approximately $2.75 billion. Additionally, consistent with managements commitment to driving mid-teens growth, the Company projects 2024 Adjusted EBITDA to be greater than $495 million.
Related news for (SGRY)
- SURGERY PARTNERS, INC. and Bain Capital Conclude Discussions
- Surgery Partners, Inc. Announces First Quarter 2025 Results; Reaffirms Full Year 2025 Guidance
- Surgery Partners, Inc. Announces Fourth Quarter and Full Year 2024 Results; Sets 2025 Guidance
- Surgery Partners, Inc. Confirms Receipt of Non-Binding Acquisition Proposal from Bain Capital